biotechconnection.com

Chemaphor Inc. (TSX VENTURE:CFR) a biotechnology research and development company, is pleased to announce it has entered into a strategic relationship with the Allied Biotech Corporation of Taiwan. With this, Chemaphor has signed a Manufacturing Development Agreement with Allied Biotech for the development, manufacture and exclusive five year supply of Chemaphor’s OxBC compound. Dr. Paul Dick, CEO of Chemaphor, said “We are very pleased to have achieved this very important milestone on the path towards the commercialization of OxBC. We believe that our relationship with Allied Biotech establishes the supply framework to meet the demands for the various markets that we intend to pursue. We are delighted to have Allied Biotech Corporation as a collaborative partner. Not only do they have world class manufacturing experience in making ß-carotene and other compounds, but they also have outstanding experience in formulation technologies, which is important to us as we move forward into other projected applications of OxBC beyond the first application as a feed additive for food production animals”.

Simon Chen, Director of Allied Biotech, concurs, “We are very excited with this opportunity to work with such an innovative and outstanding company like Chemaphor on the commercialization of OxBC. The Chemaphor alliance will provide Allied with new opportunities to utilize Allied’s production know how and expand our businesses beyond the traditional markets. Together with Chemaphor’s entrepreneurial style, we believe that a perfect match has been created to realize the successful commercialization of OxBC and further market entrances beyond the first applications.

About OxBC

Chemaphor Inc., has developed a product, OxBC, comprised of a multitude of carotenoid oxidation products, that demonstrates a wealth of biological activities, including the ability to enhance the immune system of animals. As an immune modulator that can prime the innate immune system to more rapidly and effectively respond to incipient microbial infections, OxBC offers exciting opportunities in the field of non-antibiotic products for enhancing growth and feed efficiency of animals used in food production. OxBC is a new type of a natural health product that by helping animals maintain optimal immune function and health is expected to address the growing world-wide need for alternatives to antibiotics for promoting productivity and helping reduce disease in multiple sectors of the livestock agriculture industry.

About Chemaphor Inc.

Chemaphor Inc. (www.chemaphor.com) uses its core expertise in organic chemistry to develop premium products for the animal health, skin care cosmetics, pharmaceutical and specialty chemical markets. The Company’s focus is on two proprietary products, a non pharmaceutical product OxBC and a lead cancer drug compound OCL-1. Chemaphor’s goal is to fully exploit its proprietary platform of carotenoid oxidation compounds by finding recognized partners to commercialize its products in multiple, large markets.

About Allied Biotech Corporation

In January 2002 Allied Biotech Corporation was formed as a subsidiary of Allied Industrial Corp., Ltd Group, with the purpose of focusing entirely on the carotenoid business. Earlier, in 2000 and 2001 Allied successfully launched its Beta-carotene products to the global food and supplement industries under the brand name Altratene^®, providing an alternative choice in the market. Today Allied Biotech Corporation has become one of the worlds leading manufacturers and suppliers of carotenoids.

The Altratene^® products are manufactured in a new large scale, and state-of-the-art facility in Taiwan and are animal-, BSE- and GMO-free. Additionally, they are Kosher and Halal certified and the facility holds all appropriate certifications ie. ISO9001:2000, ISO22000 and HACCP issued by SGS United Kingdom Ltd..

The product portfolio includes formulations such as oily suspensions and solutions, cold water dispersible powders and emulsions for food, feed and dietary supplement applications. Allied strives to be known as “The Carotenoid Company”, as it is the only company, which is solely focusing on bringing innovative formulations of carotenoids to the market.

You can learn more about Allied on www.altratene.com

Forward-looking statements

This news release contains forward-looking information. These statements relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management of Chemaphor Inc. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Chemaphor Inc. does not assume any obligation to update or revise them to reflect new events or circumstances. (Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release)

SOLARVEST BIOENERGY INC. (TSX VENTURE:SVS) (”Solarvest” or the “Company”), wishes to announce its non-brokered private placement, pursuant to which the investors will purchase from the Company up to 500,000 common shares at a price of $0.20 per share for gross proceeds of $100,000.

The private placement will be entirely subscribed by Related Parties of the Company and is anticipated to close on or about June 26, 2009. The shares will be subject to resale restrictions for a period of four months from the closing date under applicable securities legislation. Completion of the private placement will be subject to a number of conditions including the approval of the TSX Venture Exchange.

Proceeds from this private placement will be used as general working capital to assist with the restructuring of the Company.

About Solarvest

Solarvest is a research and development company in the biotechnology sector. The Company is committed to the development of sustainable and renewable energy sources to meet growing energy demands and environmental challenges. Solarvest has acquired the rights to a biologically-based hydrogen producing technology, which provides a controlled method for turning on and off genes in algae resulting in the continuous production of hydrogen gas.

The statements made in this Press Release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company’s expectations and projections.

The TSX Venture Exchange has neither approved nor disapproved the contents of this Press Release.

Evogene Ltd. (TASE: EVGN) today announced a collaboration with Syngenta Biotechnology, Inc. focusing on identifying plant genes related to soybean nematode resistance. Under the agreement, Syngenta will receive exclusive licensing rights to candidate genes discovered by Evogene for use in soybean.

Soybean nematode is a soil parasite which attacks the roots of developing plants, and is one of the most devastating and yield limiting pests of soybean. Soybean growers may lose more than 20 percent of their yield to this pest, while defenses against it are limited. It is estimated that soybean nematode causes losses in the United States alone exceeding one billion dollars annually.

“We are very pleased by this collaboration with Syngenta and we look forward to working with the Syngenta team on this key trait for soybean,” stated Ofer Haviv, Evogene’s President and CEO. “Plant pest protection traits, such as nematode resistance, have a strong impact on farm productivity hence Evogene intends to expand use of its predictive technologies for gene discovery in this field,” Mr. Haviv concluded.

“Syngenta is a leader in advanced breeding to bring our grower customers the best choices to protect yield against soybean pests,” stated Roger Kemble, Head Syngenta Crop Genetics Research. “This collaboration complements our in-house trait discovery program, creating new sources of genes for biotech traits to strengthen our current offering.”

Under this collaboration agreement, Evogene will provide Syngenta with candidate genes discovered by Evogene’s computational gene discovery technology, the ‘ATHLETE,’ that are predicted to improve nematode resistance. Syngenta will evaluate candidate genes in its soybean research and development program. Syngenta may commercialize improved soybean seeds developed through this collaboration.

Specific details of the agreement were not disclosed.

About Evogene

Evogene is a world leading developer of improved plant traits. The company’s proprietary product development platform combines state-of-the-art computational gene discovery technology (The ‘ATHLETE’), plant and field validation capabilities and unique selection systems. Evogene’s current programs focus on the improvement of key plant traits, such as yield and stress tolerance, and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the agro-biotech and alternative energy industries. Evogene’s headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene’s website at www.evogene.com.

This press release contains “forward-looking statements.” These statements include words like “may,” “expects,” “believes,” “scheduled,” “potentially” and “intends,” and they describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Evogene Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Stem Cell Therapy International, Inc. (OTCBB: SCII), through its wholly owned subsidiary AmStem International, Inc., announced today that it has started the process to enable the Company to distribute Histostem and other stem cell related products.

In anticipation of the finalization of the merger between Stem Cell Therapy International, Inc. and Histostem, David Stark, SCTI President and CEO, has been working closely with Histostem management to prepare the supply channels and to network with various retailers to enable AmStem International, Inc. to begin US distribution and immediately bolster the company’s cash flow. Details about the manufacturing and shipping of the Stem Cell Facial Cream, for example, have been worked out and are ready for implementation.

“The response to our Stem Cell Facial Cream has been extremely positive,” informs Mr. Stark, “and because we have a proven market presence in Asia, proprietary supply chain, GMP-approved manufacturing facility, and some very promising study results, we are ready to partner with a major distributor right now.”

AmStem International is also seeking investigators for a clinical study of the highest caliber, to compare its Stem Cell Facial Cream with others on the market. “Our experience with clinical trials is crucial,” claims Mr. Stark. “We will be conducting a scientifically and statistically valid study, IRB-approved, and ethically sound. It will be conducted with GCP standards set by FDA, ICH, and other regulatory agencies. This study will compare our Stem Cell Facial Cream vs. inactive placebo and 3 competing products in a controlled, randomized protocol.” He adds, “This is attracting leaders in the field as investigators, and we are confident that our study results will be phenomenal.”

Stem Cell Therapy International, Inc. continues to work on the necessary steps to finalize the merger, and both sides are working diligently to manage its many details. “We will continue to collaborate closely with Histostem to ensure the greatest benefit for our stockholders and investors,” adds Mr. Stark.

About Stem Cell Therapy International, Inc.

Stem Cell Therapy International, Inc. (OTCBB: SCII) is in the field of regenerative medicine. SCII is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products. Further information about Stem Cell Therapy International, Inc. can be found by contacting David Stark, President, at the email posted below.

About AmStem International, Inc.

AmStem International, Inc. is a new biotechnology company based in Northern California, in the watershed of stem cell innovation fueled by President Obama’s recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Further information about AmStem International, Inc. can be found by contacting David Stark, SCTI President, at the email posted below.

About Histostem Corporation, Ltd:

Histostem Co., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full-time employees and 28 part-time employees. Histostem’s intellectual property portfolio consists of five patents that have been granted and six patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. Further information about Histostem Corporation, Ltd. can be found by contacting David Stark, SCTI President, at the email posted below.

Forward-Looking Statements

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Stem Cell Therapy International, Inc., may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, our ability to successfully complete the merger, successfully complete clinical trials; our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.